The Consistency Code: Evaluating Protein & Cytokine Uniformity in Equine UC Allografts
- Aug 8, 2025
- 2 min read
Updated: Apr 23
This summary document highlights the lot-to-lot consistency of a cryopreserved equine umbilical cord (UC) allograft; equicenta™ CTM, as demonstrated through proteomic and cytokine analyses across multiple donors and batches. These results were first published in Bertone AL et al. “Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study.” BMC Medicine, 2025
Study Overview
Objective:
To evaluate the consistency of protein content and cytokine profile in cryopreserved UC allograft.
Methods:
Mass spectrometry (MS) and ELISA were used to assess protein abundance and cytokine levels in samples from 11 donors.
Proteomic Consistency Across Donors and Batches
A total of +2,600 proteins were identified. Of these, 80 proteins exhibited high abundance (TSC ≥ 100), and 224 proteins showed moderate abundance (TSC ≥ 40), with a coefficient of variation (CV) of 16.1%.
Proteins with TSC ≥ 40 were consistently present and functionally relevant (e.g., collagens, glycoproteins).
Triplicate samples from a single donor showed <5% coefficient of variation in abundance proteins, indicating high batch consistency
Functions included structural support, antioxidant protection, and regulation of inflammation.
ELISA Cytokine Consistency
Cytokine levels (e.g., IL-1ra, IL-10, VEGF) were measured in UC suspension.
Inflammatory cytokines (e.g., IL-1, IL-2, IL-4) were low or near detection limits.
Anti-inflammatory markers (IL-1ra, IL-10) and growth factors (VEGF, HA) were consistently present.
Low variability across triplicates confirmed reproducibility.
Conclusion
The cryopreserved UC allograft demonstrated a highly consistent protein and cytokine profile across donors and batches. These findings support its reliability and reproducibility as a biologic scaffold for musculoskeletal applications.
Conclusion
The cryopreserved UC allograft demonstrated a highly consistent protein and cytokine profile across donors and batches. These findings support its reliability and reproducibility as a biologic scaffold for musculoskeletal applications.
Ready to Explore equicenta™ CTM for Your Practice?
The peer-reviewed data speaks for itself: consistent protein profiles, proven biocompatibility, and measurable clinical outcomes in musculoskeletal conditions.
Comments